SGF29 and neoplasm: Murakami et al. found that SGF29 could enhance c-Myc-mediated malignant transformation (Murakami et al., 2014); nevertheless, our data revealed that it is downregulated in tumor samples, while its enrichment predicts better clinical outcomes, indicating that it is a tumor suppressor gene.